Trial site
Reumedika Sp. z o.o.
Poznan, 60-446, PolandEU-13 widening countryNot linked to an institution yet
- 10running trials
- 6closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 24 trials
- Phase 13 trials
- Phase 41 trial
- Status
- Completed6 trials
- Active, not recruiting5 trials
- Recruiting4 trials
- Not yet recruiting1 trial
- Lead sponsor
- MoonLake Immunotherapeutics AG3 trials
- Bristol-Myers Squibb2 trials
- Enlivex Therapeutics Ltd.2 trials
- IGM Biosciences Inc.2 trials
- Takeda2 trials
- and 5 more
Running trials
Recruiting
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter
Study of Intra-Articular Allocetra in Participants with Primary Knee
Osteoarthritis.
2025-524668-39-00· Phase 2· Enlivex Therapeutics Ltd.· Source
Recruiting
Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
NCT07580716· Phase 2· Enlivex Therapeutics Ltd.· Source
Contact: Wieslawa Porawska, MD
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· Phase 3· Takeda· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1)
2025-521315-39-00· Phase 1· Grey Wolf Therapeutics Limited· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· Phase 3· Takeda· Source
Active, not recruiting
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· Phase 4· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202· Phase 3· Bristol-Myers Squibb· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis
2024-510826-16-00· Phase 3· Mabxience Research S.L.· Source
Completed
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
2024-514981-37-00· Phase 2· Synact Pharma ApS· Source
Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease
2024-512986-15-00· Phase 2· Kiniksa Pharmaceuticals GmbH· Source
Completed
A Phase 1b Study of Imvotamab in Severe Systemic Lupus Erythematosus
2023-506499-29-00· Phase 1· IGM Biosciences Inc.· Source
Completed
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
2023-505127-31-00· Phase 1· IGM Biosciences Inc.· Source
Completed
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435· Phase 3· Bristol-Myers Squibb· Source
Report an error